A phase II clinical trial of diaziquone in the treatment of patients with recurrent endometrial carcinoma. A Gynecologic Oncology Group study.

Abstract

Twenty-six patients with measurable endometrial cancer refractory to standard therapy received AZQ [1,4-cyclohexadiene-1,4-dicarbamic acid, 2,5-bis(1-aziridinyl)3,6,dioxo,diethyl ester, NSC 182986] 22.5 mg/m2 diluted in 150 ml normal saline intravenously every three weeks. Thirteen patients experienced no toxicity and the dose in those patients was increased to 30 mg/m2 after the first course. The median number of courses given was 2.5 (range 1-9). The leukocyte count fell below 3000/microliter in 12 patients, and below 1000/microliter in two. The platelet count fell below 100,000/microliter in 12 patients, and below 25,000/microliter in one. Cumulative hematologic toxicity was not seen. One clinical complete response and one partial response were observed. Eight patients had stable disease. Median time to disease progression was 2 months. Median survival was 5.9 months. At this dose and schedule AZQ does not appear to have significant activity in recurrent endometrial cancer.

• Authors: R E Slayton, J A Blessing, P J DiSaia, G Phillips
• Journal: American journal of clinical oncology (Am J Clin Oncol) Vol. 11 Issue 6 Pg. 612-3 (Dec 1988) ISSN: 0277-3732 [Print] United States
• PMID: 3055931 (Publication Type: Clinical Trial, Journal Article, Multicenter Study, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Aziridines
• Azirines
• Benzoquinones
• diaziquone

Topics

• Aged
• Aziridines (therapeutic use)
• Azirines (therapeutic use)
• Benzoquinones
• Drug Evaluation
• Female
• Humans
• Middle Aged
• Multicenter Studies as Topic
• Neoplasm Recurrence, Local
• Uterine Neoplasms (drug therapy)